- NCIt
- C3829
Loading cancer entity…
Loading cancer entity…
Clinical trials
15 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01207492 | Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor | completed | Phase 2 | 17 | Andrew J. Wagner, MD, PhDOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05349643 | A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT | completed | Phase 2 | 20 | AmMax Bio, Inc.INDUSTRY | 3 | Jul 5, 2024 | clinicaltrials |
| NCT04731675 | An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee | completed | Phase 2 | 11 | AmMax Bio, Inc.INDUSTRY | 4 | Jun 27, 2024 | clinicaltrials |
| NCT02471716 | Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor |
Data updated 22 days agoSource updated Feb 20, 2026source: clinicaltrials
| completed |
| Phase 1 / Phase 2 |
| 66 |
| Five Prime Therapeutics, Inc.INDUSTRY |
| 6 |
| Aug 31, 2021 |
| clinicaltrials |
| NCT01643850 | MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) | completed | Phase 2 | 36 | Novartis PharmaceuticalsINDUSTRY | 2 | Jan 5, 2021 | clinicaltrials |
| NCT01261429 | Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) | completed | Phase 2 | 50 | Centre Leon BerardOTHER | 5 | Apr 16, 2013 | clinicaltrials |